We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 26% below its sector, cheaper than its peers on earnings.
Beijing Chunlizhengda Medical Instruments Co., Ltd. operates as a specialist in orthopedic medical devices. Its core activities encompass the development, manufacturing, and marketing of surgical implants, instruments, and related medical supplies. While primarily focused on the People's Republic of China, its product portfolio prominently features implantable orthopedic solutions, particularly artificial joint prostheses and spinal systems. The company distributes its offerings mainly through a network of channel partners, engages in ODM/OEM collaborations, and supplies hospitals directly, all under its established Chunli brand. Additionally, Beijing Chunlizhengda extends its reach by exporting products to various international markets. Established in 1998, the firm maintains its headquarters in Beijing, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 688236.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
